Differential expression of CD10 in prostate cancer and its clinical implication

BackgroundCD10 is a transmembrane metallo-endopeptidase that cleaves and inactivates a variety of peptide growth factors. Loss of CD10 expression is a common, early event in human prostate cancer; however, CD10 positive cancer cells frequently appear in lymph node metastasis. We hypothesize that prostate tumors expressing high levels of CD10 have a more aggressive biology with an early propensity towards lymph node metastasis.MethodsEighty-seven patients, 53 with and 34 without pathologically organ confined prostate cancer at the time of radical prostatectomy (RP), were used for the study. Fourteen patients with lymph node metastasis found at the time of surgery were identified and included in this study. Serial sections from available frozen tumor specimens in OCT were processed for CD10 immunohistochemistry. Cancer glands were graded for the presence and intensity of CD10 staining, and overall percentage of glands staining positive was estimated. Clinical characteristics including pre- and post-operative PSA and Gleason score were obtained. A similar study as a control for the statistical analysis was performed with CD13 staining. For statistical analysis, strong staining was defined as > 20% positivity based on the observed maximum separation of the cumulative distributions.ResultsCD10 expression significantly correlated with Gleason grade, tumor stage, and with pre-operative serum PSA. Seventy percent of RP specimens from patients with node metastasis showed strong staining for CD10, compared to 30% in the entire cohort (OR = 3.4, 95% CI: 1.08–10.75, P = 0.019). Increased staining for CD10 was associated with PSA recurrence after RP. CD13 staining did not correlate significantly with any of these same clinical parameters.ConclusionThese results suggest that the expression of CD10 by prostate cancer corresponds to a more aggressive phenotype with a higher malignant potential, described histologically by the Gleason score. CD10 offers potential clinical utility for stratifying prostate cancer to predict biological behavior of the tumor.

[1]  Jared C Roach,et al.  Application of affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression , 2005, BMC Cancer.

[2]  A. Oudes,et al.  HSP27 and HSP70 interact with CD10 in C4‐2 prostate cancer cells , 2007, The Prostate.

[3]  S. Horvath,et al.  Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer , 2003, The Prostate.

[4]  D. Goodlett,et al.  Stromal mesenchyme cell genes of the human prostate and bladder , 2005, BMC urology.

[5]  Takanori Hattori,et al.  CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma. , 2003, Thyroid : official journal of the American Thyroid Association.

[6]  R. P. Becker,et al.  Detection of neutral endopeptidase 24.11 (neprilysin) in human hepatocellular carcinomas by immunocytochemistry. , 1997, Anticancer research.

[7]  M. Albrecht,et al.  Identification and characterization of neutral endopeptidase (EC 3. 4. 24. 11) from human prostasomes–localization in prostatic tissue and cell lines , 2001, The Prostate.

[8]  J. Nesland,et al.  CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression , 2004, Modern Pathology.

[9]  U. Rebmann,et al.  Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. , 1998, International journal of molecular medicine.

[10]  A. Belldegrun,et al.  Lineage relationship between LNCaP and LNCaP‐derived prostate cancer cell lines , 2004, The Prostate.

[11]  Yukihiko Sato,et al.  Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon , 1996, Journal of Gastroenterology.

[12]  Catherine Magill,et al.  Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression , 1998, Nature Medicine.

[13]  Jean Kanitakis,et al.  Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin , 2002, Melanoma research.

[14]  L. True,et al.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. , 2004, The American journal of pathology.

[15]  A. Roessner,et al.  Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells , 2004, Clinical & Experimental Metastasis.

[16]  H. Lilja,et al.  Expression and immunolocalisation of neutral endopeptidase in prostate cancer. , 2003, European urology.

[17]  J. Manivel,et al.  The pattern of CD10 expression in selected pathologic entities of the prostate gland. , 2003, Human pathology.

[18]  M. Tatematsu,et al.  Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion , 2001, International journal of cancer.

[19]  S. Taneja,et al.  Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer , 2004, Clinical Cancer Research.

[20]  M. Riggs,et al.  Stage at presentation and survival of white and black patients with prostate carcinoma , 1993, Cancer.

[21]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Neoptolemos,et al.  Heat shock protein expression independently predicts clinical outcome in prostate cancer. , 2000, Cancer research.

[23]  K. Pienta,et al.  Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. , 2000, Journal of the National Cancer Institute.

[24]  Lawrence D True,et al.  Transcriptomes of human prostate cells , 2006, BMC Genomics.